Show simple item record

Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorTarruella, M. M.
dc.contributor.authorForster, M.
dc.contributor.authorPeguero, J. A.
dc.contributor.authorClay, T.
dc.contributor.authorFelip, E.
dc.contributor.authorIams, W.
dc.contributor.authorRoxburgh, P.
dc.contributor.authorde Speville, B. D.
dc.contributor.authorBajaj, P.
dc.contributor.authorMueller, C.
dc.contributor.authorTriebel, F.
dc.date.accessioned2022-04-28T13:57:39Z
dc.date.available2022-04-28T13:57:39Z
dc.date.issued2022en
dc.identifier.citationKrebs MG, Majem Tarruella M, Forster M, Peguero JA, Clay T, Felip E, et al. 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S33.en
dc.identifier.doi10.1016/j.annonc.2022.02.020en
dc.identifier.urihttp://hdl.handle.net/10541/625149
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.02.020en
dc.titleResults of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma ptsen
dc.typeMeetings and Proceedingsen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2022-06-28T09:48:38Z


Files in this item

Thumbnail
Name:
Krebs.pdf
Size:
88.12Kb
Format:
PDF
Description:
Identified with Open Access button
Download

This item appears in the following Collection(s)

Show simple item record